Home › Research › Biomarkers
Plasma neurofilament light chain mediates the effect of subsyndromal symptomatic depression on cognitive decline in older adults
Chunhua Zhang, Bingyu Li, Kok Pin Ng, Guojuan Huang, Xijin Wang, Min Kong, Maowen Ba. Frontiers in aging neuroscience, 2025-05-14
Topic: Brain imaging, connectivity and assessment
Plain-language summary
Participants with SSD exhibited a greater increase in plasma NfL levels and more pronounced declines in global cognition, memory, executive function, language, and processing speed over 2 years compared to non-SSD participants. The rate of change in plasma NfL levels significantly mediated the relationship between SSD and accelerated cognitive decline, particularly in global cognition, memory, language, and processing speed. Plasma NfL, which is related to neuroaxonal damage, may partially mediate the association between SSD and accelerated cognitive decline in non-demented older adults. These findings suggest that dynamic changes in plasma NfL levels may reflect early neurobiological alterations associated with SSD and could help identify individuals at increased risk of cognitive deterioration over a 2-year period.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhang, C., Li, B., Ng, K. P., Huang, G., Wang, X., Kong, M., et al. (2025). Plasma neurofilament light chain mediates the effect of subsyndromal symptomatic depression on cognitive decline in older adults. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2025.1547394
Vancouver
Zhang C, Li B, Ng KP, Huang G, Wang X, Kong M, et al. Plasma neurofilament light chain mediates the effect of subsyndromal symptomatic depression on cognitive decline in older adults. Frontiers in aging neuroscience. 2025. doi:10.3389/fnagi.2025.1547394. PMID: 40438503.
BibTeX
@article{zhang2025-40438503,
author = {Zhang, Chunhua and Li, Bingyu and Ng, Kok Pin and Huang, Guojuan and Wang, Xijin and Kong, Min and Ba, Maowen},
title = {{Plasma neurofilament light chain mediates the effect of subsyndromal symptomatic depression on cognitive decline in older adults}},
journal = {Frontiers in aging neuroscience},
year = {2025},
doi = {10.3389/fnagi.2025.1547394},
pmid = {40438503},
url = {https://doi.org/10.3389/fnagi.2025.1547394}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Participants with SSD exhibited a greater increase in plasma NfL levels and more pronounced declines in global cognition, memory, executive function, language, and processing speed over 2 years compared to non-SSD participants.
- The rate of change in plasma NfL levels significantly mediated the relationship between SSD and accelerated cognitive decline, particularly in global cognition, memory, language, and processing speed.
- Plasma NfL, which is related to neuroaxonal damage, may partially mediate the association between SSD and accelerated cognitive decline in non-demented older adults.
- These findings suggest that dynamic changes in plasma NfL levels may reflect early neurobiological alterations associated with SSD and could help identify individuals at increased risk of cognitive deterioration over a 2-year period.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthModerate
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 26 of the 56 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40438503) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 26 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 26 of the 56 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also in Biomarkers
139 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.